Genentech
Roche subsidiary Genentech expands in manufacturing
March 31, 2015Manufacturing and Production, Sales and Marketing Genentech, Roche, hillsboro, manufacturing, oregon
Californian drugmaker Genentech is planning a $125 million expansion at its Hillsboro manufacturing centre in Oregon. The Roche subsidiary plant …
23andMe to move into drug development
March 16, 2015Medical Communications, Research and Development, Sales and Marketing 23andME, DNA, Genentech, Pfizer, google
The Google-backed DNA test company 23andMe has announced plans to start using genetic data to design new drugs. In recent …
Late-stage successes for Amgen and Roche
February 5, 2015Sales and Marketing Amgen, Bendamustine, Gazyva, Genentech, Humira, Levact, Napp, Roche, adalimumab, obinutuzumab
Roche and Amgen have both posted successful late-stage trial results that they say will contribute to their applications for regulatory …
Genentech and Human Longevity ink genomics deal
January 19, 2015Research and Development, Sales and Marketing 23andME, DNA, Genentech, Illumina, hli, human longevity
Genentech is partnering with US genetics firm Human Longevity (HLI) in another 2015 genomics deal to continue its push into …
Roche buys French biotech for €470 million
January 19, 2015Sales and Marketing Foundation, Genentech, Orphan, Roche, TRO19622, olesoxime, sma, trophos
Roche is buying France-based biotech Trophos in a deal worth up to €470 million in order to gain access to …
Roche stakes $1 billion in cancer gene research firm
January 12, 2015Research and Development, Sales and Marketing Cancer, Foundation Medicine, Genentech, Roche, genomics, jp morgan
Roche has announced a huge billion-dollar investment in the cancer genomics research firm Foundation Medicine. Timed with the beginning of …
Genentech makes $10m gene testing outlay
January 8, 2015Medical Communications, Research and Development, Sales and Marketing 23andME, DNA, Genentech, MHRA, Pfizer, Roche
Genentech has thrown its weight behind the contentious DNA testing company 23andMe, by agreeing a deal to buy the genomic …
Gilead secures senior head from Genentech
December 17, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Genentech, Gilead, Philippe Bishop
Dr Philippe Bishop is joining the California-based biopharma firm Gilead from Genentech to be the company’s senior vice president of …
NICE wants more Xolair data
November 19, 2014Sales and Marketing Genentech, NHS, NICE, Novartis, UK, Xolair, hives, omalizumab
Novartis has been asked in draft guidance to give NICE more information before the watchdog can recommend its veteran asthma …
Roche pays $8.3bn for InterMune
August 26, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Genentech, IPF, Illumina, InterMune, Roche
Roche has stumped up $8.3 billion in cash to pay for US biotech firm InterMune and will gain access to …
Mixed bag for Genentech dementia drug
July 18, 2014Research and Development, Sales and Marketing Alzheimer's, Genentech, crenezumab, dementia
A Phase II clinical trial for Genentech’s investigational Alzheimer’s drug failed to meet its primary endpoints – but the company …
Novartis makes Alzheimer’s deal
July 16, 2014Research and Development, Sales and Marketing Alzheimer's, Genentech, Novartis, bai, epstein
Novartis is to collaborate with the Banner Alzheimer’s Institute (BAI) to test two of the Swiss company’s investigational anti-amyloid treatments. …
Genentech to buy Seragon
July 3, 2014Sales and Marketing Genentech, Roche, breast cancer, oncology, serds
Roche subsidiary Genentech is to pay around $1.7 billion for biotech firm Seragon Pharmaceuticals to secure its portfolio of potential …
Genome-driven lung cancer trial launches
June 18, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, Genentech, MedImmune, Pfizer, genome, lung cancer
Amgen, Genentech, Pfizer, AstraZeneca and MedImmune – AstraZeneca’s global biologics R&D arm – have each put investigative treatments into a …
NICE rejects Kadcyla
April 23, 2014Sales and Marketing CDF, Cancer, Genentech, Kadcyla, NHS, NICE, Roche
NICE has delivered a severe blow to Roche by rejecting its breast cancer ‘smart bomb’ Kadcyla for NHS use in …
Latest content
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
